Overexpression of miR-221 and miR-222 in the cancer stroma is associated with malignant potential in colorectal cancer

被引:29
|
作者
Iida, Michihisa [1 ]
Hazama, Shoichi [1 ,2 ]
Tsunedomi, Ryouichi [1 ]
Tanaka, Hironori [1 ]
Takenouchi, Hiroko [1 ]
Kanekiyo, Shinsuke [1 ]
Tokumitsu, Yukio [1 ]
Tomochika, Shinobu [1 ]
Tokuhisa, Yoshihiro [1 ]
Sakamoto, Kazuhiko [1 ]
Suzuki, Nobuaki [1 ]
Takeda, Shigeru [1 ]
Ueno, Tomio [3 ]
Yamamoto, Shigeru [1 ]
Yoshino, Shigefumi [1 ,4 ]
Fujita, Koji [5 ]
Kuroda, Masahiko [5 ]
Nagano, Hiroaki [1 ]
机构
[1] Yamaguchi Univ, Sch Med, Dept Gastroenterol Breast & Endocrine Surg, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan
[2] Yamaguchi Univ, Sch Med, Dept Translat Res & Dev Therapeut Canc, Ube, Yamaguchi 7558505, Japan
[3] Kawasaki Med Sch, Dept Digest Surg, Kurashiki, Okayama 7010192, Japan
[4] Yamaguchi Univ, Ctr Oncol, Ube, Yamaguchi 7558505, Japan
[5] Tokyo Med Univ, Dept Mol Pathol, Tokyo 1608402, Japan
关键词
colorectal cancer; stromal tissue; tumor microenvironment; microRNA; liver metastasis; microarray analysis; MICRORNAS; PROGRESSION; EXPRESSION; RECURRENCE; MICROARRAY; RESISTANCE; PROGNOSIS; SURVIVAL; INVASION; TARGET;
D O I
10.3892/or.2018.6575
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cancer stroma is important in cancer development, however, whether the aberrant expression of microRNAs (miRNAs) in the cancer stroma is associated with cancer progression remains to be fully elucidated. The aim of the present study was to identify the miRNAs associated with liver metastasis in the cancer stroma of human colorectal cancer (CRC). Using laser capture microdissection, cancer stroma was obtained from the primary lesion of six patients with CRC with liver metastasis (CRCwLM) and six patients with CRC without liver metastasis (CRCwoLM), and miRNA microarray analysis was performed. Candidate miRNA expression status in the stroma was validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis in 40 CRC cases (wLM, n=20; woLM, n=20), and the association between miRNA expression and clinicopathological factors was assessed in 101 advanced CRC samples. The localization of candidate miRNAs in CRCs was analyzed using in situ hybridization analysis (ISH). The microarray analysis identified six miRNAs with expression differing between the CRCwLM and CRCwoLM cancer stroma. Validation using RT-qPCR analysis of the stroma showed that the expression levels of miR-221 and miR-222 in the cancer stroma were significantly higher in CRCwLM than in CRCwoLM. The RT-qPCR analysis of 101 CRC samples showed that a high expression level of miR-221 or miR-222 in the cancer stroma was associated with liver metastasis, distant metastasis, and shorter overall survival rate of patients with CRC (P<0.05). Increased levels of miR-221 and miR-222 were observed in cancer cells and in fibroblasts in the stromal tissue in the ISH analysis. The results suggested that the overexpression of miR-221 and miR-222 in the cancer stroma is associated with the metastatic activity and malignant potential in patients with CRC.
引用
收藏
页码:1621 / 1631
页数:11
相关论文
共 50 条
  • [11] Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets
    Simone Treiger Sredni
    Maria de Fátima Bonaldo
    Fabrício Falconi Costa
    Chiang-Ching Huang
    Christopher Allan Hamm
    Veena Rajaram
    Tadanori Tomita
    Stewart Goldman
    Jared Marshall Bischof
    Marcelo Bento Soares
    Child's Nervous System, 2010, 26 : 279 - 283
  • [12] Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis
    Ravegnini, Gloria
    Cargnin, Sarah
    Sammarini, Giulia
    Zanotti, Federica
    Bermejo, Justo Lorenzo
    Hrelia, Patrizia
    Terrazzino, Salvatore
    Angelini, Sabrina
    CANCERS, 2019, 11 (07)
  • [13] Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells
    Yamashita, Ryo
    Sato, Mitsuo
    Kakumu, Tomohiko
    Hase, Tetsunari
    Yogo, Naoyuki
    Maruyama, Eiichi
    Sekido, Yoshitaka
    Kondo, Masashi
    Hasegawa, Yoshinori
    CANCER MEDICINE, 2015, 4 (04): : 551 - 564
  • [14] New insights of miR-221 and miR-222 cluster functions in Burkitt lymphoma
    Consiglio, Jessica
    De Luca, Luciana
    Acunzo, Mario
    Galasso, Marco
    Rocci, Alberto
    Sapienza, Maria-Rosaria
    Piccaluga, Pier Paolo
    Vecchione, Andrea
    Zanesi, Nicola
    Volinia, Stefano
    Croce, Carlo Maria
    Pichiorri, Flavia
    CANCER RESEARCH, 2012, 72
  • [15] MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma
    Chun-Zhi Zhang
    Jun-Xia Zhang
    An-Ling Zhang
    Zhen-Dong Shi
    Lei Han
    Zhi-Fan Jia
    Wei-Dong Yang
    Guang-Xiu Wang
    Tao Jiang
    Yong-Ping You
    Pei-Yu Pu
    Jin-Quan Cheng
    Chun-Sheng Kang
    Molecular Cancer, 9
  • [16] miR-21, miR-221, and miR-222 upregulation in lung cancer promotes metastasis by reducing oxidative stress and apoptosis
    Tepebasi, Muhammet Yusuf
    Ozturk, Oender
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2023, 69 (06):
  • [17] The inhibition effect of expressions of miR-221 and miR-222 on glioma and corresponding mechanism
    Zhang, Z.
    Cui, B. Z.
    Wu, L. H.
    Xu, Q. L.
    Wang, Z.
    Yang, B.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2014, 115 (11): : 685 - 691
  • [18] Severity of Hypertension does not Correlate with Increased miR-221 and miR-222 Expression
    Woods, T. C.
    HYPERTENSION, 2013, 62 (03)
  • [19] Inhibition of Cancer Stem Cells Growth with Silibinin Encapsulated in Nanoparticles with Deregulation of miR-34a, miR-221, and miR-222
    Hosseinzadeh, Samaneh
    Kararoudi, Alireza Nouhi
    Eshkelani, Seyed Milad Mousavi
    Pakizehkar, Safura
    Sohi, Alireza Naderi
    Najafi, Farhood
    Ranji, Najmeh
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2023, 25 (04)
  • [20] miR-221/222: promising biomarkers for breast cancer
    Chen, Wei-Xian
    Hu, Qing
    Qiu, Man-Tang
    Zhong, Shan-Liang
    Xu, Jin-Jin
    Tang, Jin-Hai
    Zhao, Jian-Hua
    TUMOR BIOLOGY, 2013, 34 (03) : 1361 - 1370